title: New insulins and quality of life.
abstract: Extreme customization of treatment is even more necessary when dealing with young diabetic patients as compared with adult patients. From diagnosis the pediatrician must introduce treatment in the less traumatic way possible so that the child does not perceive a derangement of his/her life. In order to preserve the quality of life the diabetic child must be able to attend birthday parties, participate in sports, and generally lead a full social life just like his/her friends. In the present paper we evaluate the characteristics of the new insulin analogues and their advantages and disadvantages with respect to the needs of patients. The wide spectrum of available insulin formulations including also the new short- and long- acting insulin analogues are of great help in conceiving a therapeutic plan closely adherent to the patient's needs. As an example, in children aged less than 5-6 years a short acting insulin may be injected immediatly after the meal. The same insulin may be useful in older patients with an incostant style of life due to social activities. On the other hand the "old" insulins may still be used for the therapeutic plan in patients with a more constant life style as to the physical exercise and intervals between the meals. In conclusion, the quality of life in the children and adolescents with diabetes may be accomplished with a flexible and personalized therapeutic plan and a great attention to the education. The latter is a very important tool for the compliance and the reduction of anxiety in patients and their parents.
authors.affiliation: Department of Paediatrics, Second University of Naples, Naples, Italy. dario.iafusco@unina2.it
authors.forename: Dario
authors.initials: D
authors.lastname: Iafusco
mesh_terms: D000293:Adolescent; D019090:Case Management; D002648:Child; D003692:Delayed-Action Preparations; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000523:psychology*; D016883:Diabetic Ketoacidosis / Q000209:etiology; D004334:Drug Administration Schedule; D005260:Female; D006207:Half-Life; D006801:Humans; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000145:classification / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061267:Insulin Aspart; D000069036:Insulin Glargine; D061268:Insulin Lispro; D049528:Insulin, Long-Acting; D008297:Male; D010349:Patient Compliance; D010353:Patient Education as Topic; D011788:Quality of Life; D012917:Social Adjustment; D016896:Treatment Outcome
chemical_list: D003692:Delayed-Action Preparations; D007328:Insulin; D061268:Insulin Lispro; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine; D061267:Insulin Aspart